July 13, 2005 – Federal Register Recent Federal Regulation Documents

On January 7, 2005, the Department of Commerce published the preliminary results of the administrative review of the antidumping duty order on stainless steel wire rod (SSWR) from India. The review covers three companies for the period December 1, 2002, through November 30, 2003. We gave interested parties an opportunity to comment on the preliminary results. Based on our analysis of the comments received, we have made changes, including correction of a clerical error, in the margin calculations. The final weighted-average margins are listed below in the ``Final Results of Review'' section of this notice.

The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) [44 U.S.C. 3506(c)(2)(A)]. This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. The Employment and Training Administration (ETA) is soliciting comments on revised reporting requirements for the Trade Adjustment Assistance (TAA) program. These changes are necessary to collect data to comply with the Trade Reform Act of 2002 and to be able to calculate a set of common performance measures of the outcomes achieved by the TAA program.

This provides notice of a forthcoming meeting of the Interagency Coordinating Council on Emergency Preparedness and individuals with Disabilities (ICC). Notice of this meeting is intended to inform members of the general public of their opportunity to attend the meeting. The ICC will engage in discussions related to the one year anniversary of Executive Order 13347 and review accomplishment and future goals of the ICC in implementation of this Executive Order. The meeting will be open and accessible to the general public.

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 60/010,166, filed January 5, 1996, entitled ``Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers And Methods And Kits For Targeting'' [E-002-1996/0-US-01]; United States Patent No. 6,153,430, issued on November 28, 2000, entitled ``Nucleic Acid Encoding Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers'' [E-002-1996/0-US-02]; United States Patent Application No. 09/684,599, filed October 5, 2000, entitled ``Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers And Methods And Kits For Targeting'' (E-002-1996/0-US-03); United States Patent No. 6,083,502, issued on July 4, 2000, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-US-02]; PCT Application No. PCT/US97/ 00224, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-PCT-01]; Australian Patent No. 703769, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-AU-03]; Canadian Patent No. 2241604, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002- 1996/1-CA-04]; Japanese Patent Application No. 9-525355, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-JP-06]; European Patent No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-EP-05]; Switzerland Patent Application No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-CH-07]; German Patent No. 69726404.1, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' (E-002-1996/1-DE-08); French Patent Application No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002- 1996/1-FR-09]; Italian Patent No. 05503/BE/2004, January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1T-10]; Spanish Patent No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-ES-11]; United Kingdom Patent No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-GB-12]; United States Patent No. 5,320,956, issued June 14, 1996, entitled ``Monoclonal Antibody'' [E-195-1990/0-US-20]; United States Patent No. 5,525,337, issued June 11, 1996, entitled ``Monoclonal Antibody Binding Cell Surface Antigen For Diagnosing Cancer'' [E-195-1990/0-US-21]; United States Patent No. 5,817,313, issued October 6, 1998, entitled ``Monoclonal Antibodies And Conjugates Thereof Useful For The Treatment Of Cancer'' [E-195-1990/0-US-22]; PCT Patent Application No. PCT/US91/ 07227, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195- 1990/0-PCT-02]; Denmark Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-DK-03]; United Kingdom Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-GB-04]; Austrian Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-AT-05]; Belgium Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-BE-06]; European Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E- 195-1990/0-EP-09]; French Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-FR-11]; German Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-DE-08]; Greece Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-GR-12]; Netherlands Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-NL-15]; Italian Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-IT-13]; Luxembourg Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-LU-14]; Spanish Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E- 195-1990/0-ES-10]; Sweden Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-SE-16]; Switzerland Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-CH-07]; Australian Patent No. 648363, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-AU-17]; Canadian Patent No. 2093928, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-CA-18]; and Japanese Patent No. 2660241, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E- 195-1990/0-JP-19] to Morphotek, Inc., which has offices in Exton, Pennsylvania. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of licensee's MORAb-009 antibody for the treatment of mesothelin-expressing cancer.

The National Aeronautics and Space Administration announces a forthcoming meeting of the NASA Aeronautics Research Advisory Committee (ARAC), Airspace Systems Program Subcommittee (ASPS).